Exclusive: JP Morgan leading process for potential $3 billion AF Group sale

Reuters
04-22
Exclusive: JP Morgan leading process for potential $3 billion AF Group sale

By James Thaler

April 21 - (The Insurer) - Blue Cross Blue Shield of Michigan is working with JP Morgan on a sale process for the nearly $2 billion surplus AF Group, a commercial lines carrier that wrote nearly $2.9 billion in direct premiums in 2024, broking, carrier, and banking sources told The Insurer.

Sources said that BCBS Michigan and its advisor JP Morgan are exploring a potential transaction that could value AF Group at 1.5 times its $1.974 billion year-end 2024 policyholder surplus, meaning that a deal for the property-casualty operations could be valued at just shy of $3 billion.

Sources said JP Morgan has recently approached a number of potential strategic acquirers about exploring a deal for AF Group.

BCBS Michigan’s motivation for bringing its property-casualty insurance subsidiary to market for a sale could not immediately be confirmed.

The health insurer parent reported a $1.7 billion underwriting loss for 2024 early last month, as well as a $1.02 billion net loss on enterprise revenue of $40.6 billion.

AF Group and JP Morgan did not immediately respond to a request for comment.

Statutory data from SNL Capital IQ shows that AF Group wrote a little more than $1.5 billion in workers compensation direct premiums in 2024, along with around $450 million in other liability premiums, which is the insurance group’s second largest business line.

AF Group also wrote $291 million in commercial auto business last year as well as $308 million in combined fire and allied lines, $244 million in commercial multi-peril business, and $62 million in marine lines.

A move by BCBS Michigan to sell AF Group represents a significant shift in strategy for the non-profit mutual health insurance company, after AF Group acquired commercial lines insurer AmeriTrust, formerly known as Meadowbrook, from Chinese owner Fosun in early 2023.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10